Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial
A Phase I clinical trial of the gene-editing therapy VERVE-102 showed promising results, with a single infusion reducing bad cholesterol (LDL) by up to 62% in patients receiving the highest dose. The treatment uses mRNA-based base editing to permanently disable the PCSK9 gene in the liver, which regulates cholesterol levels. While the study is small (35 participants) and preliminary, the drug appears safe with sustained effects observed over the follow-up period.
Why it matters
This represents a potential paradigm shift in treating cardiovascular disease, moving from daily medication to a one-time genetic intervention that could permanently lower cholesterol and significantly reduce the risk of heart disease.
Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial - Ars Technica
The article provides a factual, scientific summary of a clinical trial. It balances the positive results with necessary caveats regarding the small sample size, the preliminary nature of the data, and the potential side effects, maintaining a neutral and informative tone.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in